CA2866718A1 - Compositions, procedes, et kits pour reguler le metabolisme energetique - Google Patents

Compositions, procedes, et kits pour reguler le metabolisme energetique Download PDF

Info

Publication number
CA2866718A1
CA2866718A1 CA2866718A CA2866718A CA2866718A1 CA 2866718 A1 CA2866718 A1 CA 2866718A1 CA 2866718 A CA2866718 A CA 2866718A CA 2866718 A CA2866718 A CA 2866718A CA 2866718 A1 CA2866718 A1 CA 2866718A1
Authority
CA
Canada
Prior art keywords
composition
subject
leucine
increase
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2866718A
Other languages
English (en)
Other versions
CA2866718C (fr
Inventor
Michael ZEMEL
E. Douglas Ii Grindstaff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nusirt Sciences Inc
Original Assignee
Nusirt Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nusirt Sciences Inc filed Critical Nusirt Sciences Inc
Publication of CA2866718A1 publication Critical patent/CA2866718A1/fr
Application granted granted Critical
Publication of CA2866718C publication Critical patent/CA2866718C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Tea And Coffee (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicinal Preparation (AREA)
CA2866718A 2012-03-08 2013-03-08 Compositions, procedes, et kits pour reguler le metabolisme energetique Active CA2866718C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261608595P 2012-03-08 2012-03-08
US61/608,595 2012-03-08
US201261656407P 2012-06-06 2012-06-06
US61/656,407 2012-06-06
US13/662,345 US9198454B2 (en) 2012-03-08 2012-10-26 Compositions, methods, and kits for regulating energy metabolism
US13/662,345 2012-10-26
PCT/US2013/030044 WO2013134736A1 (fr) 2012-03-08 2013-03-08 Compositions, procédés, et kits pour réguler le métabolisme énergétique

Publications (2)

Publication Number Publication Date
CA2866718A1 true CA2866718A1 (fr) 2013-09-12
CA2866718C CA2866718C (fr) 2019-06-18

Family

ID=49114651

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2866718A Active CA2866718C (fr) 2012-03-08 2013-03-08 Compositions, procedes, et kits pour reguler le metabolisme energetique

Country Status (7)

Country Link
US (4) US9198454B2 (fr)
EP (1) EP2822579B1 (fr)
JP (2) JP6210517B2 (fr)
AU (2) AU2013229779B2 (fr)
CA (1) CA2866718C (fr)
HK (1) HK1205942A1 (fr)
WO (1) WO2013134736A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013012760A1 (fr) 2011-07-15 2013-01-24 Numeta Sciences, Inc. Compositions et procédés de modulation de voies métaboliques
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
CA2891335C (fr) 2012-11-13 2021-05-04 Nusirt Sciences, Inc. Compositions et methodes permettant d'accroitre le metabolisme energetique
CA2902879C (fr) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine et acide nicotinique reduisant les taux de lipides
KR20160119863A (ko) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. 간 지방증의 감소 또는 예방을 위한 조성물 및 방법
EP3197437A4 (fr) * 2014-09-24 2018-05-23 NuSirt Sciences, Inc. Compositions, méthodes et kits de traitement du diabète et/ou de l'hyperlipidémie
WO2017040407A1 (fr) * 2015-09-01 2017-03-09 Nusirt Sciences, Inc. Compositions et procédés destinés à réduire ou à prévenir la stéatohépatite non alcoolique (shna)
US11701336B2 (en) 2015-10-30 2023-07-18 Yasumasa Kato Method of determining composition effective for treating diabetes
JP6250196B2 (ja) * 2015-10-30 2017-12-20 恭正 加藤 糖尿病治療用組成物
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
PE20200747A1 (es) 2017-08-14 2020-07-24 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
CN112056272A (zh) * 2020-09-16 2020-12-11 华中农业大学 一种评价甜味剂摄入对小鼠影响的方法
WO2024186730A1 (fr) * 2023-03-03 2024-09-12 Grads Innovation Compositions permettant une oxydation métabolique améliorée d'acides gras

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
JP3219838B2 (ja) 1992-05-12 2001-10-15 沖電気工業株式会社 半導体素子の製造方法
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
LU88369A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Acides aminés à chaînes ramifiées
US5339771A (en) 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5616569A (en) 1994-03-28 1997-04-01 The Iams Company Pet food product containing fermentable fibers and process for treating gastrointestinal disorders
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
EP0873754B1 (fr) 1996-01-09 2003-07-30 Riken Compositions d'acides amines
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
GB9723059D0 (en) 1997-10-31 1998-01-07 Mars Uk Ltd Pet food
CN1305485A (zh) 1998-05-04 2001-07-25 安德里斯·约翰尼斯·凯塞尔 单体,寡聚和多聚科诺威纳格尔缩合产物
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
CN1161101C (zh) 1998-12-17 2004-08-11 阿尔扎有限公司 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
EP1169322B8 (fr) 1999-03-08 2006-09-13 Medicure Inc. Analogues de pyridoxal destines aux troubles provoques par une carence en vitamine b6
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
AU7596100A (en) 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6527711B1 (en) 1999-10-18 2003-03-04 Bodymedia, Inc. Wearable human physiological data sensors and reporting system therefor
US6280779B1 (en) 1999-12-28 2001-08-28 Colgate-Palmolive Company Pet food for maintaining normal bowel health
EP1662989B1 (fr) 2000-06-16 2014-09-03 BodyMedia, Inc. Systeme de surveillance et de gestion du poids du corps et d'autres etats physiologiques comprenant un programme interactif et personnalise et des capacites d'intervention et de rapport
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
ES2311482T3 (es) 2000-12-29 2009-02-16 Martin Francis Gannon Producto alimenticio para animales.
BR0207948A (pt) 2001-03-09 2004-07-27 Produits Nestel S A Soc D Composição que melhora os déficits fisiológicos relacionados com a idade e que aumenta a longevidade
US6338862B1 (en) 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
CA2466415C (fr) 2001-11-09 2020-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1.beta., un nouvel homologue du pgc-1 et leurs utilisations
US20030187055A1 (en) 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
KR101072885B1 (ko) 2002-05-17 2011-10-17 듀크 유니버시티 비만치료방법
WO2004002565A1 (fr) 2002-06-26 2004-01-08 Alza Corporation Piston peu flexible efficace d'un point de vue volumique pour systemes d'administration de medicaments osmotiques
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
EP1551282B1 (fr) 2002-10-09 2015-11-18 BodyMedia, Inc. Appareil de detection, de reception, de derivation et d'affichage d'informations physiologiques et contextuelles humaines
US20050064070A1 (en) 2002-10-11 2005-03-24 Jeffrey Liebrecht Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
CA2518735C (fr) 2003-03-13 2012-05-15 Vector Usa Inc. Film comprenant un liquide absorbe dans celui-ci
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
WO2004082402A1 (fr) 2003-03-18 2004-09-30 Novartis Ag Compositions comprenant des acides gras et des acides amines
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
EP1638586B1 (fr) 2003-05-14 2008-03-26 Indus Biotech Pvt. Ltd. Composition synergique destinee au traitement du diabete sucre
WO2005003766A2 (fr) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Procedes de regulation du metabolisme et de la fonction mitochondriale
EP1643863A2 (fr) 2003-07-10 2006-04-12 Carl A. Forest Aliments, boissons, condiments, epices et sauces pour salades a complements specialises
JP2005097273A (ja) * 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
EP2319410A1 (fr) 2003-09-12 2011-05-11 BodyMedia, Inc. Appareil pour la mesure de paramètres cardiaques
US7495101B2 (en) 2003-11-19 2009-02-24 Dsm Ip Assets B.V. Manufacture of vitamin B6
WO2005049006A1 (fr) 2003-11-21 2005-06-02 Ajinomoto Co., Inc. Remede contre les diabetes
ES2378768T3 (es) 2003-11-26 2012-04-17 Hill's Pet Nutrition, Inc. Método para reducir el olor de excrementos de animales de compañía
US8388949B2 (en) * 2003-12-24 2013-03-05 N.V. Nutricia Compositions comprising pantothenic acid and their use for stimulating appetite
AU2004312072B2 (en) 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
WO2006009769A1 (fr) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Formulation de liberation modifiee de memantine
WO2006001278A1 (fr) 2004-06-28 2006-01-05 Kao Corporation Activateur d'ampk
EP1786428B1 (fr) 2004-08-17 2012-05-16 The Johns Hopkins University Compositions d'inhibiteur pde5 et methodes de traitement des troubles cardiaques
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1818055A1 (fr) 2004-11-29 2007-08-15 Toyo Shinyaku Co., Ltd. Composition augmentant la capacite athletique
US20060115555A1 (en) 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
WO2006094236A1 (fr) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Dérivés de n-phénylbenzamide en tant qu'agents régulant la sirtuine
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
AU2006259619A1 (en) 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP2388263A1 (fr) 2005-08-04 2011-11-23 Sirtris Pharmaceuticals, Inc. Dérivés d'imidazo[2,1-b]thiazole comme modulateurs de sirtuin
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US20070077310A1 (en) 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
JP2007161675A (ja) * 2005-12-16 2007-06-28 Taisho Pharmaceut Co Ltd 疲労改善内服剤
CA2635655C (fr) 2006-01-10 2011-09-06 Hill's Pet Nutrition, Inc. Compositions et methodes pour promouvoir la perte de graisse
WO2007100722A2 (fr) 2006-02-28 2007-09-07 Trustees Of Boston University Procédés d'identification de facteurs associés à la croissance musculaire et leurs utilisations
US7691388B2 (en) 2006-03-24 2010-04-06 Ocean Nutrition Canada Limited Compositions comprising Porphyra and methods of making and using thereof
KR20090017502A (ko) 2006-04-05 2009-02-18 체마폴, 인코포레이티드. 식료품 보충제 및 그의 용도
JP2007306851A (ja) * 2006-05-18 2007-11-29 仁 ▲吉▼井 食塩組成物およびその製造方法
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
PL2038252T3 (pl) 2006-07-12 2017-03-31 University Of Tennessee Research Foundation Podstawione acyloanilidy i sposoby ich zastosowania
JP2008063328A (ja) 2006-08-07 2008-03-21 Kowa Co 糸球体疾患治療剤
JP5507802B2 (ja) 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
AU2007341981A1 (en) 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
TWI440456B (zh) 2007-01-16 2014-06-11 用於治療代謝性症候群之新穎化合物
US20080319855A1 (en) 2007-02-16 2008-12-25 Stivoric John M Advertising and marketing based on lifeotypes
WO2008103179A1 (fr) 2007-02-23 2008-08-28 Hill's Pet Nutrition, Inc. Compositions et méthodes de contrôle du poids chez des animaux
WO2008115563A1 (fr) * 2007-03-19 2008-09-25 University Of Florida Research Foundation, Inc. Composition de nutriment liquide pour améliorer la performance
US20080233244A1 (en) 2007-03-23 2008-09-25 Solae, Llc Animal food compositions and treats
WO2008119070A1 (fr) 2007-03-28 2008-10-02 Trustees Of Boston University Procédés de traitement utilisant des modulateurs de sirt et compositions contenant des modulateurs de sirt1
US20080268038A1 (en) * 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
WO2008143182A1 (fr) 2007-05-17 2008-11-27 Kaneka Corporation Composition contenant un polyphénol dérivé de la réglisse
WO2008153945A2 (fr) 2007-06-06 2008-12-18 University Of South Florida Compositions nutraceutiques de co-cristal
WO2008157537A2 (fr) 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions et procédés d'utilisation pour traiter ou prévenir des troubles liés aux lipides
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
WO2009002867A2 (fr) 2007-06-26 2008-12-31 Nutrition 21, Inc. Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
WO2009033034A1 (fr) 2007-09-07 2009-03-12 Nike, Inc. Ensemble de dispositif portable ayant une fonctionnalité athlétique
US20110082189A1 (en) 2007-10-23 2011-04-07 President And Fellows Of Harvard College Use of compounds activating sirt-3 for mimicking exercise
US20090156648A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
CA2714181C (fr) 2008-02-04 2013-12-24 Mercury Therapeutics, Inc. Modulateurs de l'ampk
EP2252955A1 (fr) 2008-03-03 2010-11-24 Nike International Ltd. Système d équipement de sport interactif
EP2265341A1 (fr) 2008-04-02 2010-12-29 Nike International Ltd. Ensemble dispositif pouvant être porté présentant une fonctionnalité pour un athlète
GB0809665D0 (en) 2008-05-28 2008-07-02 Mars Uk Ltd Food product
EP2308493A4 (fr) 2008-07-07 2013-05-01 Mochida Pharm Co Ltd Agent améliorant ou thérapeutique pour une dyslipidémie
JP2012504554A (ja) 2008-08-15 2012-02-23 ネステク ソシエテ アノニム エネルギー代謝を向上させる方法
BRPI0919409A2 (pt) 2008-09-19 2015-12-15 Nestec Sa suporte nutricional para prevenir ou moderar a neutropenia ou paralisia da medula óssea durante o tratamento anticâncer
US20100173024A1 (en) 2008-12-01 2010-07-08 LifeSpan Extension, LLC Methods and compositions for altering health, wellbeing, and lifespan
CN106913340B (zh) 2009-04-26 2020-12-08 耐克创新有限合伙公司 在运动手表系统中的gps特征和功能
BRPI0904259A2 (pt) 2009-05-06 2012-02-28 Provets-simões Laboratório Ltda suplemento alimentar para pássaros em fase reprodutiva
US8377473B2 (en) 2009-07-01 2013-02-19 Magceutics, Inc. Slow release magnesium composition and uses thereof
US8691303B2 (en) 2009-07-31 2014-04-08 The Iams Company Dusted animal food
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
CN102630161A (zh) 2009-09-18 2012-08-08 珀利弗诺斯自然有限公司 通过用岩藻黄质和石榴油酸的组合激活去乙酰化酶Sirtuin来延缓衰老过程的方法
WO2011051974A1 (fr) 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformine et acides aminés alpha
US8173181B2 (en) 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
WO2011087708A1 (fr) 2010-01-13 2011-07-21 Dodds W Jean Compositions alimentaires pour animaux destinées à favoriser l'assainissement du foie et à atténuer les dysbioses intestinales
US20120309716A1 (en) 2010-02-03 2012-12-06 Kao Corporation Motor Function Improver
US20110208153A1 (en) 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102077936B (zh) * 2010-09-20 2013-04-24 王强 一种糖尿病患者专用的海洋特膳食品
US9167991B2 (en) 2010-09-30 2015-10-27 Fitbit, Inc. Portable monitoring devices and methods of operating same
WO2012060884A1 (fr) 2010-11-04 2012-05-10 Nestec S.A. Procédés et compositions pour prévenir et traiter l'arthrose
ES2834986T3 (es) 2011-01-07 2021-06-21 Anji Pharma Us Llc Terapias basadas en ligandos de receptores quimiosensoriales
WO2012097064A1 (fr) 2011-01-13 2012-07-19 Abbott Laboratories Compositions nutritionnelles et procédés pour contrôler le glucose dans le sang
US20120231087A1 (en) 2011-03-07 2012-09-13 Olympic Seafood Compositions And Methods for Nutritional Supplementation
WO2013012760A1 (fr) 2011-07-15 2013-01-24 Numeta Sciences, Inc. Compositions et procédés de modulation de voies métaboliques
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US20160073659A1 (en) 2013-03-15 2016-03-17 Nusirt Sciences, Inc. Compositions, methods, and kits for treatment of pets
KR20160119863A (ko) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. 간 지방증의 감소 또는 예방을 위한 조성물 및 방법

Also Published As

Publication number Publication date
JP2015510888A (ja) 2015-04-13
US9901573B2 (en) 2018-02-27
AU2013229779B2 (en) 2017-11-09
US20130237605A1 (en) 2013-09-12
US9408410B2 (en) 2016-08-09
JP2018012722A (ja) 2018-01-25
US20170368045A1 (en) 2017-12-28
AU2018200861A1 (en) 2018-02-22
US9198454B2 (en) 2015-12-01
JP6210517B2 (ja) 2017-10-11
US20170000777A1 (en) 2017-01-05
AU2013229779A1 (en) 2014-10-23
HK1205942A1 (en) 2015-12-31
CA2866718C (fr) 2019-06-18
EP2822579B1 (fr) 2019-06-26
US9713609B2 (en) 2017-07-25
EP2822579A4 (fr) 2015-10-28
US20160113317A1 (en) 2016-04-28
EP2822579A1 (fr) 2015-01-14
WO2013134736A1 (fr) 2013-09-12

Similar Documents

Publication Publication Date Title
US9901573B2 (en) Compositions, methods, and kits for regulating energy metabolism
US10076507B1 (en) Compositions and methods for modulating metabolic pathways
US9724319B2 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
US20180235970A1 (en) Compositions and methods for increasing energy metabolism
WO2010141889A1 (fr) Utilisation de méthylsulfonylméthane comme agent de masquage du goût
WO2018085440A1 (fr) Réduction et prévention de la perte musculaire par l'acide linoléique conjugué (cla) et la vitamine d

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180215